Synairgen has announced revised terms to its collaboration agreement with Pharmaxis and the LOXL2 programme. The group has no further financial obligations for the programme and will be paid £5m consideration plus around 17% of future partnering revenues. The group announced in September that it intends to progress SNG001 (inhaled interferon beta) into clinical development for the treatment of COPD with a short Phase II trial designed for the winter 2017/2018. The group will use the £5m consider ....
14 Dec 2017
N+1 Singer - Synairgen - Revised terms with Pharmaxis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Synairgen - Revised terms with Pharmaxis
Synairgen plc (SNG:LON) | 6.4 0 2.5% | Mkt Cap: 13.0m
- Published:
14 Dec 2017 -
Author:
Sheena Berry -
Pages:
3
Synairgen has announced revised terms to its collaboration agreement with Pharmaxis and the LOXL2 programme. The group has no further financial obligations for the programme and will be paid £5m consideration plus around 17% of future partnering revenues. The group announced in September that it intends to progress SNG001 (inhaled interferon beta) into clinical development for the treatment of COPD with a short Phase II trial designed for the winter 2017/2018. The group will use the £5m consider ....